2. Signaling Pathways
  3. GPCR/G Protein
  4. Platelet-activating Factor Receptor (PAFR)

Platelet-activating Factor Receptor (PAFR)

The platelet-activating factor receptor (PAFR) is a G-protein-coupled receptor involved in both normal physiological and numerous pathophysiological processes. PAFR responds to platelet-activating factor (PAF), a phospholipid mediator of cell-to-cell communication that exhibits diverse physiological effects. Stimulation of the PAFR via binding of platelet-activating factor (PAF) elicits diverse and potent biological activities and plays a profound role in acute inflammation, allergic disorders, endotoxic shock, and anaphylaxis. PAF is a potent and versatile mediator of inflammation that is produced by numerous cell types and tissues, and particularly by leukocytes.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N0784R
    Ginkgolide B (Standard)
    		Antagonist
    Ginkgolide B (Standard) is the analytical standard of Ginkgolide B. This product is intended for research and analytical applications. Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activating factor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments.
    Ginkgolide B (Standard)
  • HY-W040221
    Butanoyl PAF
    		Agonist
    Butanoyl PAF, a compound closely related to Azelaoyl PC (HY-134154), maintains over 10% of the agonist potency of platelet-activating factor (PAF). Butanoyl PAF's concentration in oxidized low-density lipoprotein surpasses that of enzymatically generated PAF by more than 100-fold.
    Butanoyl PAF
  • HY-N12995
    α-Bulnesene
    		Antagonist
    α-Bulnesene is a novel PAF receptor antagonist with the IC50 of 17.62 μM. α-Bulnesene can be isolated from Pogostemon cablin. α-Bulnesene shows inhibitory effect on platelet-activating factor and arachidonic acid induced rabbit platelet aggregation.
    α-Bulnesene
  • HY-108908A
    Modipafant
    Modipafant (UK-80067), the (+)-enantiomer of UK-74505, is a potent, orally active, and selective platelet-activating factor (PAF) antagonist. Modipafant exhibits approximately double the intrinsic potency of UK-74505.
    Modipafant
  • HY-108634S
    Apafant-d8
    Apafant-d8 is the deuterium labeled Apafant. Apafant (WEB 2086) is a potent platelet-activating factor (PAF) antagonist, inhibits PAF binding to human PAF receptors with a Kiof 9.9 nM. Apafant increases the gene expression of PAF-r, α-globin, β-globin, decreases the c-myb gene expression. Apafant shows a protective effect on alkyl-PAF-mediated lethalit.
    Apafant-d8
  • HY-19126
    CL-184005
    		Antagonist
    CL-184005 is an antagonist for platelet-activating factor (PAF), that inhibits the PAF-induced platelet aggregation with IC50 of 600 nM and 510 nM, in human and rabbit platelet-rich plasma. CL-184005 protects the rats from endotoxin-induced gastrointestinal damage and hypotension. CL-184005 exhibits potential attenuating Gram-negative bacterial sepsis.
    CL-184005
  • HY-171253
    Clotizolam
    		Antagonist
    Clotizolam is a thienobenzodiazepine derivative that has antagonistic activity against platelet-activating factor (PAF). Clotizolam possesses sedative, anxiolytic, anticonvulsant,and muscle relaxant effects.
    Clotizolam
  • HY-N3436
    Kadsurin A
    		Antagonist
    Kadsurin A is a new lignan can be isolated from Piper futokadsura. Kadsurin A is a platelet activating factor (PAF) receptor antagonist that weakly inhibits the binding of PAF to its receptor.
    Kadsurin A
  • HY-136791
    BN52115
    		Antagonist
    BN 52115, a platelet-activating factor antagonist, has demonstrated the ability to mitigate bronchopulmonary changes in vivo.
    BN52115
  • HY-106833
    SDZ-62-434 free base
    		Antagonist
    SDZ-62-434 (free base) is a platelet-activating factor (PAF) antagonist. SDZ-62-434 (free base) has antiproliferative activity in human solid and haematological malignancies.
    SDZ-62-434 free base
  • HY-132190
    Hexanolamino PAF C-16
    		Antagonist
    Hexanolamino PAF C-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine) is a Platelet-activating Factor Receptor (PAFR) Modulator with partial agonist activity. Hexanolamino PAF C-16 induces platelet aggregation and macrophage production but fails to increase [Ca2+]i in platelets, suggesting that PAF receptors may interact with PAF receptors through Ca2+-dependent and -independent pathways. Related to platelet aggregation.
    Hexanolamino PAF C-16
  • HY-121377
    Epiyangambin
    		Antagonist
    Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells).
    Epiyangambin
  • HY-19125
    BN-50726
    		Antagonist
    BN-50726 is a potent platelet-activating factor (PAF) receptor antagonist. BN-50726 inhibits PAF-induced effects (e.g., [3H]-serotonin release and hypotension) (IC50= 5.40 nM). BN-50726 is promising for research of PAF-mediated pathological processes (e.g., inflammation, anaphylaxis, hypotension).
    BN-50726
  • HY-N3643
    Cryptomeridiol
    		Inhibitor
    Cryptomeridiol is a platelet-activating factor (PAF) receptor binding inhibitor. Cryptomeridiol has melanogenesis inhibitory activity in the α-MSH (HY-P0252)-stimulated B16 melanoma cells.
    Cryptomeridiol
  • HY-132210
    rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane
    		Antagonist
    rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane (compound 6) is a platelet-activating factor receptor (PAFR) antagonist with a Ki of 0.3 µM.
    rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane
  • HY-116120
    N-Acetyldesloratadine
    		Antagonist 99.93%
    N-Acetyldesloratadine (SCH-37370) is a potent, orally active dual antagonist of platelet-activating factor (PAF) and histamine. N-Acetyldesloratadine inhibits PAF-induced aggregation of human platelets, with an IC50 of 0.6 µM. N-Acetyldesloratadine can be used for the study of allergic diseases, such as asthma.
    N-Acetyldesloratadine
  • HY-116400
    BN 50341
    		Antagonist
    BN 50341 is an orally active anticalcic agent and a benzazepine derivative. BN 50341 decreases the in vivo electrically induced thrombus formation in rat or guinea-pig artery and can be utilized in cardiovascular research.
    BN 50341
  • HY-19184
    MKC-963
    		Inhibitor
    MKC-963 is an orally active and potent inhibitor targeting platelet aggregation-related pathways. MKC-963 exerts antithrombotic activity by inhibiting platelet aggregation, and can also induce autoinduction, i.e., upregulating the mRNA expression and activity of CYP3A4 enzyme to accelerate its own metabolism in vivo. MKC-963 is promising for research of platelet aggregation-related diseases (e.g., thrombosis).
    MKC-963
  • HY-N2247A
    (+)-Guaiacin
    (+)-Guaiacin is a compound extracted of the bark of Machilus wangchiana Chun. (Lauraceae). (+)-Guaiacin shows potent in vitro activities against the release of β-glucuronidase in rat polymorphonuclear leukocytes (PMNs) induced by platelet-activating factor (PAF) .
    (+)-Guaiacin
  • HY-123367
    Rubraxanthone
    		Inhibitor
    Rubraxanthone is a compound with multiple biological activities. Its pharmacokinetic parameters were determined in mice and it showed a certain concentration variation pattern in plasma after oral administration.
    Rubraxanthone
Cat. No. Product Name / Synonyms Application Reactivity